Navigation Links
Oncology Alliance: Apeiron, CCRI and SIOPEN Join Forces Against Neuroblastoma
Date:6/22/2011

VIENNA, June 22, 2011 /PRNewswire/ --


 

Vienna based biotech company APEIRON Biologics AG (Apeiron) strengthens its oncology pipeline: The company will support the clinical development of an immune therapy against high-risk neuroblastoma that is being conducted by the Children's Cancer Research Institute (CCRI) and the European Neuroblastoma Research Network (SIOPEN). It is presently under investigation in a phase III trial across various European clinical centers. In return, Apeiron obtains the rights to file for regulatory approval and to market the final product. The approach is based on a monoclonal antibody (ch14.18) and constitutes Apeiron's most advanced project. It also marks another milestone for the company and its development strategy to treat neuroblastoma. This strategy was initiated earlier this year with the licensing of a clinical phase II project from Merck KGaA.

Today, Vienna based Apeiron announced the conclusion of an agreement with the Children's Cancer Research Institute (CCRI) and the European Neuroblastoma Research Network (SIOPEN). Thereby, Apeiron obtains the rights to further develop, file for regulatory approval and market the antibody ch14.18. This monoclonal antibody exhibits therapeutic effect against high-risk neuroblastoma, an aggressive form of infant cancer. The antibody specifically targets the antigen GD2, a feature on the surface of neuroblastoma cells and thereby initiates an immune reaction against these cells.

As part of the agreement, Apeiron will provide substantial support for an ongoing European clinical phase III trial with ch14.18. Due to the limited number of clinical centers specializing in the treatment of high-risk neuroblastoma, Apeiron is considering marketing the therapy on its own.

The Austrian company Polymun Scientific, a long-time business partner of Apeiron, has already been producing clinical supplies for the CCRI/SIOPEN spo
'/>"/>

SOURCE APEIRON Biologics AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Best of ASCO Features Two Studies Led by US Oncology Research Affiliated Physicians
2. Cell Therapeutics Completes Type A Meeting With FDAs Division of Oncology Drug Products: Guidance Provided for Resubmission of Pixantrone NDA for Consideration of Accelerated Approval
3. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
4. Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
5. Kendle Appoints Robert Shepard, MD, FACP Executive Director, Oncology
6. Investment in Oncology Drug Development Remains Strong as 133 Companies Initiate Late-Stage Clinical Trials Representing a 21% Increase
7. Roche and Clovis Oncology to Co-Develop EGFR Companion Diagnostic
8. Translational Sciences Corporation to Launch OncoTrac™ at the American Society of Clinical Oncology (ASCO) Annual Meeting
9. US Oncology Research Affiliated Physicians to Present at 2011 ASCO Annual Meeting
10. Astellas Announces Vice President of Sales and Marketing for U.S. Oncology Franchise
11. Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  Hill-Rom (NYSE: ... Providence Health ( Renton, WA ), the ... expands the companies, existing relationship as Hill-Rom now becomes ... Bariatric capital bed frame and surface products. ... systems in the U.S.  It operates 34 hospitals, 475 ...
(Date:9/23/2014)... Sept. 23, 2014  MEDIMETRIKS PHARMACEUTICALS today announced ... Resnick have been elected to Medimetriks, Board ... Mr. Lary, who will serve on Medimetriks, Audit ... experience to the Company.  Mr. Lary is currently ... a leading institutional investment firm.  Mr. Lary is ...
(Date:9/23/2014)... Sept. 23, 2014   COTA, Inc. today ... $7 million Series A funding round led by Horizon ... is the first big data platform designed by practicing ... analysis for cancer care in support of healthcare,s new ... to expand development of the COTA platform, hire biostatisticians, ...
Breaking Medicine Technology:Hill-Rom Announces Seven-Year, Sole-Source Contract with Providence Health 2Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 4
... MARINO, Calif. March 25, 2011 VG Energy, ... VRAL ), announced today that it ... to verify lab results on a large scale for the development ... VG Energy has developed proprietary technology, with results ...
... Ltd. (Nasdaq: SVA ), a leading provider ... Weidong Yin, President and CEO, and Ms. Helen Yang, ... UBS Greater China Healthcare Corporate Day.  The conference will ... March 28th to March 29.  The Sinovac team will ...
Cached Medicine Technology:VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 2VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 3VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 4Sinovac Participates in UBS Greater China Healthcare Corporate Day 2
(Date:9/23/2014)... (PRWEB) September 23, 2014 Mel Frank, ... about cultivating, growing and harvesting marijuana. He is perhaps ... the field and he’ll be leading a special elective ... am to 5:00 pm at Oaksterdam University ... law, botany and nomenclature, harvesting and manicuring, and identifying ...
(Date:9/23/2014)... that FDG-PET technology is less accurate in diagnosing ... infections like histoplasmosis or tuberculosis are common. ... lead to unnecessary tests and surgeries for patients, ... Histoplasmosis and other fungal diseases are linked to ... and are found in soils. , The study ...
(Date:9/23/2014)... San Diego, CA (PRWEB) September 23, 2014 ... website daily regarding all the latest information from the ... announced on September 5, that its Private Label Jalapeno ... glass and small stones. Publix Jalapeno Bagels ... in the bakery department. , Taking into consideration ...
(Date:9/23/2014)... 2014 (HealthDay News) -- A test used to diagnose lung ... certain lung infections are more common, a new analysis says. ... through the use of what,s known as functional imaging. For ... is used, according to the study authors. Cancerous tumors ... parts of the lungs that don,t have cancer, according to ...
(Date:9/23/2014)... 23, 2014 Grinnell Mutual seeks ... projects in the Midwest. Working Together Making It ... non-profit organizations with projects positively impacting their communities. ... marketplace make their communities a better places,” said ... Community Relations Barb Baker. “Their leadership—as coaches, as ...
Breaking Medicine News(10 mins):Health News:Special Elective Course Added to Oaksterdam University Schedule; Unique Opportunity to Learn From the “Godfather of Cannabis” Mel Frank on September 27, 2014 2Health News:Study questions accuracy of lung cancer screens in some geographic regions 2Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:Grinnell Mutual Invites Submissions for Innovative, Collaborative Local Projects in Its Second Annual Working Together Making It Better Promotion 2
... death rates, longer hospital stays and greater costs , , ... (GI) bleeding admitted to hospitals on weekends are more ... to two studies that analyzed U.S. patient data. ... upper gastrointestinal hemorrhage (NVUGIH) admitted on weekends were 36 ...
... of Your Mental Health Talk Radio www.blogtalkradio.com/yourmentalhealth when ... Men Are From Mars, Women Are From Venus ... new book When Mars and Venus Collide: Improving Relationships ... on Thursday, March 5th at 8 PM EST/5 PM ...
... Hit Unprecedented Lows; Approximately Half of Hospitals UnprofitableANN ... margin of U.S. hospitals has fallen to zero ... hospital finances published today. Driven largely by ... apparent in all types of hospitals - small, ...
... than 52,000 patients from eight countries has shown that ... improvements and greater patient satisfaction. , The findings, ... International Journal of Clinical Practice , show that 53 ... less than seven per cent, the target set by ...
... users with Zix CorporationDALLAS, March 2 Zix Corporation ... Blue Shield of Massachusetts (BCBSMA) today announced a contract ... Zix Corporation and Blue Cross Blue Shield of Massachusetts ... entering its sixth year. Under the contract terms, ...
... Edwin Ishoo , MD, an Otolaryngologist and facial ... the use of both minimally invasive and non-invasive techniques ... procedures implemented by Dr. Ishoo are also designed to ... activities as soon as possible."We are committed to using ...
Cached Medicine News:Health News:Weekend Admission May Be Riskier for GI Bleeding 2Health News:John Gray Will Discuss His New Book Why Mars and Venus Collide 2Health News:Thomson Reuters Study Tracks Impact of Recession on Hospitals 2Health News:Thomson Reuters Study Tracks Impact of Recession on Hospitals 3Health News:Insulin drug study shows significant improvements in more than 52,000 diabetic patients 2Health News:Insulin drug study shows significant improvements in more than 52,000 diabetic patients 3Health News:Zix Corporation and Blue Cross Blue Shield of Massachusetts Expand the Industry's Largest e-Prescribing Program 2Health News:Edwin Ishoo MD Providing Non-Invasive Cosmetic Procedures, Minimizing Recovery Time 2
The Tano Asymmetrical Microforceps features an offset tip which allows optimal visualization along the entire tip length. Versatile tip design targets ILM, fine epiretinal membranes and diabetic or P...
Microforceps : Asymmetrical Endgripping Forceps...
Pic forceps design that is slightly curved; tips have special "surface treatment" for enhanced manipulation of the retina....
Microforceps : Eckardt Endgripping Forceps...
Medicine Products: